Establishment of a Brain and Spinal Tumor Tissue Bank

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish a Brain and Spinal Tumor Tissue/Specimen repository to serve as a resource for current and future scientific studies.

Detailed Description
-----------------
Glioblastoma multiforme (GBM) is the most common and lethal primary Brain and Spinal Tumor in adults. It is nearly uniformly fatal, with a median survival of approximately one year, despite modern treatment modalities. Efforts to understand why some patients live longer or shorter than the average may provide insights into the biology of these neoplasms. For years, researchers have tried to identify independent predictors that could help in treatment planning. With the recent interest in molecular biology and molecular genetics, tumor markers are now being examined as potential predictors. A marker that could predict tumor response to therapy, the likelihood of recurrence, and survival would thus be quite useful.

Official Title
-----------------
Establishment of a Brain and Spinal Tumor Tissue Bank and Clinical Data Repository for Identifying Molecular Markers of Clinical Outcome

Conditions
-----------------
Glioblastoma Multiforme, Glioma, Neuroectodermal Tumors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must have a suspected or confirmed diagnosis of Brain and Spinal Tumor Age greater than 20 Signed consent Exclusion Criteria: Known HIV infection Any other clinical condition which, in the opinion of the principal investigator, would not allow completion of this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect, annotate, and store fresh frozen specimens of normal tissue, tumors, and pre-malignant lesions for biological investigation. |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collect, process, and store serum, plasma and isolate lymphocytes from blood drawn from patients with Brain and Spinal Tumor |  | 5 years | 
| Establish a database to link materials acquisition, pathologic, and clinical information on patients who participate in the protocol |  | 5 years | 
| To utilize the clinical database to perform clinical and pathological correlation with the results of current and future scientific studies |  | 5 years | 
| To evaluate various NAT2, EGFR and MGMT for evidence of genomic and biochemical activation |  | 5 years | 
| To test the effect of small molecule inhibitors on the activation of wild-type and mutant NAT2, EGFR, MGMT and/or other potential molecular targets |  | 5 years | 
| To correlate tumor genotype and signaling abnormalities with clinical response to NAT2, EGFR, MGMT and/or other potential molecular targets inhibitors |  | 5 years | 
| Analysis of laboratory findings in relationship to patient demographics and clinical course |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tissue Bank, Glioblastoma Multiforme, NAT2, EGFR, MGMT, Brain and Spinal TumorGliomas